{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Antagonist", "query": { "intervention": "Antagonist" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 1177, "total_pages": 118, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Antagonist&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-06T13:10:42.495Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02906670", "title": "Sym013 (Pan-HER) in Patients With Advanced Epithelial Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Oncology" ], "interventions": [ { "name": "Sym013", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Symphogen A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2016-11-01", "completion_date": "2019-06", "has_results": true, "last_update_posted_date": "2020-08-28", "last_synced_at": "2026-09-06T13:10:42.495Z", "location_count": 3, "location_summary": "Nashville, Tennessee • San Antonio, Texas", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "San Antonio", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02906670" }, { "nct_id": "NCT02849548", "title": "Suvorexant and Sleep's Benefits to Therapeutic Exposure for Posttraumatic Stress Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Posttraumatic Stress Disorder" ], "interventions": [ { "name": "suvorexant", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Howard University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2017-01-03", "completion_date": "2021-05-19", "has_results": true, "last_update_posted_date": "2023-06-02", "last_synced_at": "2026-09-06T13:10:42.495Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02849548" }, { "nct_id": "NCT01071564", "title": "RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Estrogen Receptor Negative", "HER2/Neu Negative", "Progesterone Receptor Negative", "Recurrent Breast Carcinoma", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Gamma-Secretase Inhibitor RO4929097", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacogenomic Study", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Vismodegib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2009-11", "completion_date": "2014-06", "has_results": false, "last_update_posted_date": "2015-04-15", "last_synced_at": "2026-09-06T13:10:42.495Z", "location_count": 3, "location_summary": "Baltimore, Maryland • Ann Arbor, Michigan • Detroit, Michigan", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01071564" }, { "nct_id": "NCT00090116", "title": "The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Alzheimer's Disease" ], "interventions": [ { "name": "Neramexane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Forest Laboratories", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 400, "start_date": "2003-03", "completion_date": "2005-03", "has_results": false, "last_update_posted_date": "2012-03-05", "last_synced_at": "2026-09-06T13:10:42.495Z", "location_count": 34, "location_summary": "Peoria, Arizona • Phoenix, Arizona • Fresno, California + 30 more", "locations": [ { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Northridge", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00090116" }, { "nct_id": "NCT01689038", "title": "Brain Imaging Study of F17464", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "F17464", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pierre Fabre Medicament", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "MALE", "summary": "18 Years to 55 Years · Male only" }, "enrollment_count": 8, "start_date": "2012-11", "completion_date": "2013-02", "has_results": false, "last_update_posted_date": "2013-02-15", "last_synced_at": "2026-09-06T13:10:42.495Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01689038" }, { "nct_id": "NCT05463133", "title": "Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Granulomatous Disease" ], "interventions": [ { "name": "Sirolimus", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Pheripheral blood stem cells", "type": "BIOLOGICAL" }, { "name": "Emapalumab-Izsg", "type": "DRUG" }, { "name": "Tociluzumab", "type": "DRUG" }, { "name": "Total Body Irradiation", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "4 Years to 65 Years" }, "enrollment_count": 50, "start_date": "2022-07-08", "completion_date": "2032-12-31", "has_results": false, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-09-06T13:10:42.495Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05463133" }, { "nct_id": "NCT00044876", "title": "Treatment of Uterine Fibroids With CDB-2914, an Experimental Selective Progesterone Receptor Antagonist", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leiomyoma" ], "interventions": [ { "name": "CDB-2914", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "33 Years", "maximum_age": "50 Years", "sex": "FEMALE", "summary": "33 Years to 50 Years · Female only" }, "enrollment_count": 56, "start_date": "2002-09-02", "completion_date": "2015-10-01", "has_results": false, "last_update_posted_date": "2019-12-17", "last_synced_at": "2026-09-06T13:10:42.495Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00044876" }, { "nct_id": "NCT04249713", "title": "An Alternative Dose Interval Study in Participants With Hidradenitis Suppurativa Receiving Brodalumab", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Hidradenitis Suppurativa" ], "interventions": [ { "name": "Brodalumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rockefeller University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 0, "start_date": "2020-02-03", "completion_date": "2020-09", "has_results": false, "last_update_posted_date": "2020-09-04", "last_synced_at": "2026-09-06T13:10:42.495Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04249713" }, { "nct_id": "NCT04912115", "title": "Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Dyskinesias", "Movement Disorders", "Central Nervous System Diseases", "Nervous System Diseases", "Neurologic Manifestations" ], "interventions": [ { "name": "Ketamine", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PharmaTher Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "30 Years to 85 Years" }, "enrollment_count": 30, "start_date": "2021-10-05", "completion_date": "2024-03-30", "has_results": false, "last_update_posted_date": "2023-11-18", "last_synced_at": "2026-09-06T13:10:42.495Z", "location_count": 7, "location_summary": "Tucson, Arizona • Chula Vista, California • Fountain Valley, California + 3 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Chula Vista", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04912115" }, { "nct_id": "NCT04638660", "title": "Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Dim Light Vision Disturbances" ], "interventions": [ { "name": "Phentolamine Ophthalmic Solution 0.75%", "type": "DRUG" }, { "name": "Phentolamine Ophthalmic Solution Vehicle (Placebo)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ocuphire Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 144, "start_date": "2020-12-30", "completion_date": "2022-05-19", "has_results": true, "last_update_posted_date": "2025-10-14", "last_synced_at": "2026-09-06T13:10:42.495Z", "location_count": 17, "location_summary": "Newport Beach, California • Petaluma, California • Jacksonville, Florida + 12 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "Petaluma", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Pittsburg", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04638660" } ] }